Results 11 to 20 of about 196 (129)
Фармакокинетика и Фармакодинамика, 2019 While studing of experimental pharmacokinetics of the peptide analogues piracetam noopept - N-phenylacetyl-L-prolyl-glycine ethyl ester, was found the active metabolite that identificated as cyclo-L-prolylglycine (CPG).
Svetlana Boyko +2 more
doaj +6 more sources
Noopept protects ciliates Paramecium сaudatum cells from the toxic effects of heavy metal compounds
Фармакокинетика и Фармакодинамика, 2022 Background. The dipeptide drug Noopept, created at the Zakusov Institute of Pharmacology, has a wide range of pharmacological actions, including cytoprotective one.
O. V. Karpukhina +2 more
doaj +4 more sources
Фармакокинетика и Фармакодинамика, 2022 The article presents the results of studying the pharmacokinetics and enzymatic stability of a new pharmacologically active compound GZK-111– N-phenylacetyl-glycyl-L-proline ethyl ether in comparison with noopept – N-phenylacetyl-L-prolyl-glycine ethyl ...
S. S. Boyko +2 more
doaj +4 more sources
Medičnì Perspektivi, 2020 The purpose of this research is to study the specific activity of our developed nasal dosage form with n-phenylacetyl-l-prolylglycine ethyl ester. The experiments were performed on 260 white outbred rats weighing 190-220 g.
B.S. Burlaka +4 more
doaj +4 more sources
Pharmacokinetics and neurotropic effects of cyclo-L-prolylglycine and its modified analogues
Фармакокинетика и Фармакодинамика, 2022 The review presents the results of studies on the pharmacokinetics, metabolism, and bioavailability of new neurotropic dipeptide cyclo-Lprolilglycine (CPG) and their pharmacological activity.
S. S. Boyko +2 more
doaj +3 more sources
Biotechnic & Histochemistry, 2023 Diabetes mellitus (DM) is a chronic disease at all ages including childhood and puberty. Failure to treat DM can cause retinopathy, nephropathy and neuropathy. Endocrine and metabolic changes during the pubertal period complicate management of DM. Noopept is a cognitive enhancer that exhibits antidiabetic properties.
Perihan Gurbuz +3 more
openaire +4 more sources
The study of the permeability of the blood-brain barrier for new neurotropic peptide drugs
Фармакокинетика и Фармакодинамика, 2019 The paper presents the results of studies of penetration through the hemato-encephalic barrier (BBB) of rats of three new peptide drugs -modified analogues of endogenous neuropeptides and their active metabolites created in the research Zakusov institute
V. P. Zherdev +2 more
doaj +4 more sources
The Study of [3H]-Cycloprolylglycine Pharmacokinetics in Rat Blood
Фармакокинетика и Фармакодинамика, 2019 Resume. The objective of this study is to evaluate pharmacokinetic parameters of tritium-labeled cycloprolylglycine [3H] -CPG following intravenous bolus administration of 5.7 μg (2 mCi).
G. I. Kovalev +7 more
doaj +4 more sources
Фармакокинетика и Фармакодинамика, 2016 Effects of intraperitoneal and intranasal administration of peptides noopept (1 mcg/kg/day for 5 days) and semax (0,6 mcg/ kg/day for 5 days), known to produce nootropic and anxiolytic actions were tested in BALB/c mice (the Line is characterized by ...
E. V. Vasilieva +2 more
doaj +3 more sources
Фармакокинетика и Фармакодинамика, 2018 Resume. The paper presents literature data about the interspecific differences of the pharmacokinetics of peptide drugs and the results of our own studies on the inter-specific features of the pharmacokinetics of the 3 modified analogues of endogenous ...
V. P. Zherdev +5 more
doaj +3 more sources